ArticleScientific reports2026
Design and immunogenicity of a recombinant Saccharomyces boulardii secreting the P2-VP8 subunit rotavirus vaccine.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Insights into Microbiota-Vaccine Crosstalk in Humans: Mechanisms, Modulators, and Translational Horizons.Vaccines · 2026Review
- Yeasts in the gastrointestinal tract.FEMS yeast research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus is the leading cause of infectious diarrhea in children, and vaccination has significantly reduced the mortality rate. However, the current vaccines have not shown optimal effectiveness in developing countries. Regarding the treatment field, rotavirus vaccine candidates, such as probiotics, virus-like particle, and subunit vaccines, have been developed worldwide, even though their efficacy and safety remain to be improved. We designed and examined the Saccharomyces boulardii secreting P2-VP8 fusion protein as a rotavirus vaccine candidate. The immunological and physicochemical properties of the P2-VP8 fusion protein were evaluated the in silico analyses. A 3D structure of P2-VP8 was generated, refined, and validated. The immune simulation of codon-optimized P2-VP8 fusion protein was investigated by immunoinformatics servers. Then, it was confirmed that the Saccharomyces boulardii was secreting the P2-VP8 fusion protein. C57BL/6 mice were studied for immune response analyses after oral administration of the recombinant Saccharomyces boulardii. IFN-γ and IL-4 were measured to evaluate the activity of Th-1 and Th-2 lymphocytes, respectively. The CFSE [Carboxyfluorescein succinimidyl ester] assay was used for the assessment of lymphocyte proliferation. In silico results revealed that the P2-VP8 fusion protein was immunogenic and non-allergenic. Also, dynamic simulation showed the strong and stable interaction between the P2-VP8 fusion protein and immune cell receptor. Secretion of the P2-VP8 from Saccharomyces boulardii was confirmed by SDS-PAGE and western blotting assays. In vivo results denoted that recombinant Saccharomyces boulardii elicited significant differences in levels of IFN-γ and IL-4 responses compared to control groups. Furthermore, cell proliferation differences were not statistically significant. In this study, probable immunogenicity and stable binding of P2-VP8 to the immune receptor were predicted by in silico study. Recombinant Saccharomyces boulardii could secrete the P2-VP8 subunit rotavirus vaccine. However, our in vivo results demonstrated poor immunogenicity following vaccination and can be improved in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.